- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01896895
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid
Prospective, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of Two Different Doses of NT 201 in Botulinum Toxin Treatment-naïve Subjects With Blepharospasm
This phase 3 study will serve to collect efficacy and safety data of two different doses of NT 201 in subjects suffering from Bilateral Blepharospasm (BEB) who are BTX treatment-naïve.
In this study, BTX treatment-naïve subjects are defined as those who have not received BTX treatment within the last 12 months for the treatment of BEB. This definition aims to avoid bias by comparison of treatment effects in the subject's assessments. Furthermore, this study will substantiate the existing efficacy and safety database for the indication BEB.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Athens, Greece, 11521
- Merz Investigational Site #030002
-
Athens, Greece, 11526
- Merz Investigational Site #030001
-
-
-
-
-
Kuala Lumpur, Malaysia, 50586
- Merz Investigational Site #060006
-
Kuala Lumpur, Malaysia, 56000
- Merz Investigational Site #060002
-
Selangor, Malaysia, 43000
- Merz Investigational Site #060003
-
-
Penang
-
Georgetown, Penang, Malaysia, 10990
- Merz Investigational Site #060007
-
-
Sabah
-
Kota Kinabalu, Sabah, Malaysia, 88586
- Merz Investigational Site #060004
-
-
-
-
-
Colombo, Sri Lanka, 07
- Merz Investigational Site #094001
-
Colombo, Sri Lanka, 10350
- Merz Investigational Site #094005
-
Kurunegala, Sri Lanka, 60000
- Merz Investigational Site #094006
-
Nugegoda, Sri Lanka, 10250
- Merz Investigational Site #094002
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female out-patients age ≥ 18 and ≤ 80 years.
- A clinical diagnosis of bilateral BEB characterized by spontaneous, spasmodic, intermittent or persistent involuntary contractions of orbicular oculi muscles.
- A need for injection of BTX defined as a Jankovic Rating Scale [JRS] severity subscore ≥ 2.
- Treatment-naïve subject defined as at least 12 months without BTX of any serotype for the treatment of BEB before administration of IP.
Exclusion Criteria:
- Subject with any previous unsuccessful treatment with BTX of any serotype for the treatment of BEB.
- Atypical variant of BEB (e.g., apraxia of the eyelid opening) caused by inhibition of levator palpebrae muscle.
- Neuroleptic-induced blepharospasm.
- Myotomy or denervation surgery in the affected muscles (e.g., peripheral denervation, spinal cord stimulation) and surgery in the upper face.
- Generalized disorders of muscles activity (e.g., myasthenia gravis in particular ocularis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis) or any other significant neuromuscular dysfunction which might interfere with the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IncobotulinumtoxinA (Xeomin) 25U per eye
Main Period: one injection session, 25 Units per eye.
Open-Label Extension: one injection session, up to 35 Units per eye.
Mode of administration: intramuscular injection.
|
IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Main Period: 25 Units per eye.
Other Names:
IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Open-Label Extension: up to 35 Units per eye.
Other Names:
|
Experimental: IncobotulinumtoxinA (Xeomin) 12.5U per eye
Main Period: one injection session, 12.5 Units per eye.
Open-Label Extension Period: one injection session, up to 35 Units per eye.
Mode of administration: intramuscular injection.
|
IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Open-Label Extension: up to 35 Units per eye.
Other Names:
IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Main Period: 12.5 Units per eye.
Other Names:
|
Placebo Comparator: Placebo
Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session. Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection. |
IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Open-Label Extension: up to 35 Units per eye.
Other Names:
Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Double-blind MP: Change From Baseline in JRS Severity Subscore at Day 43 (Visit 4)
Time Frame: Baseline, Day 43 (Visit 4)
|
JRS severity subscore was used to classify individual symptoms of blepharospasm and to determine therapeutic efficacy.
JRS severity subscore ranges from 0 to 4, where 0: None; 1: increased blinking present with external stimuli; 2: Mild but spontaneous eyelid fluttering, definitely noticeable, possibly embarrassing, but not functionally disabling, 3: Moderate, very noticeable spasm of eyelids only, mildly incapacitating, 4: Severe, incapacitating spasm of eyelids and possibly other facial muscles.
Values represent least square (LS) mean differences between baseline and visit 4 resulting from analysis of covariance (ANCOVA) with treatment group, pooled site, and gender as fixed factors and baseline JRS severity subscore and age as covariates and missings replaced using the last observation carried forward (LOCF) method.
Negative values denote improvement, while positive values denote deterioration vs. baseline.
|
Baseline, Day 43 (Visit 4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Double-blind MP: Change From Baseline in Blepharospasm Disability Index (BSDI) at Day 43 (Visit 4)
Time Frame: Baseline, Day 43 (Visit 4)
|
BSDI is a scale for assessment of impairment of specific activities of daily living caused by blepharospasm.
BSDI consists of six items (driving a vehicle; reading; watching TV; shopping; getting about on foot (walking); doing everyday activities), each ranging from 0 (=no impairment) to 4 (=no longer possible due to illness).
The BSDI total score is a mean score for non-missing items ranging from 0 to 4. It is calculated by adding scores of all applicable and answered items, and dividing the resulting sum by the number of items answered.
Outcome values represent LS mean differences between baseline and visit 4 (visit 4 value minus baseline value) resulting from ANCOVA with treatment group, pooled site, gender as fixed factors and baseline BSDI total score, age as covariates.
Missings were replaced by the LOCF method.
Negative values denote an improvement, while positive values denote deterioration vs. baseline.
|
Baseline, Day 43 (Visit 4)
|
Double-blind MP: Patient Evaluation of Global Response (PEGR) at Final Visit (Day 43-Day 141)
Time Frame: Baseline, Final Visit (Day 43-Day 141)
|
PEGR scale is a descriptive subjective 9-point response self-rating scale ranging from "complete abolishment of signs and symptoms" (value=+4) down to "very marked worsening" (value=-4).
Outcome values represent least square means at visit 4 resulting from an ANCOVA with treatment group, pooled site, gender as fixed factors and age as covariates.
Missing were set to a zero effect (value=0).
Positive values denote an improvement, while negative values denote deterioration.
|
Baseline, Final Visit (Day 43-Day 141)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Mitsikostas DD, Dekundy A, Hanschmann A, Althaus M, Scheschonka A, Pagan F, Jankovic J. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naive subjects. Curr Med Res Opin. 2021 Oct;37(10):1761-1768. doi: 10.1080/03007995.2021.1965975. Epub 2021 Aug 24.
- Duarte GS, Rodrigues FB, Marques RE, Castelao M, Ferreira J, Sampaio C, Moore AP, Costa J. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD004900. doi: 10.1002/14651858.CD004900.pub3.
- Mitsikostas DD, Dekundy A, Sternberg K, Althaus M, Pagan F. IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naive Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial. Adv Ther. 2020 Oct;37(10):4249-4265. doi: 10.1007/s12325-020-01427-6. Epub 2020 Aug 10.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Eyelid Diseases
- Blepharospasm
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
- incobotulinumtoxinA
Other Study ID Numbers
- MRZ60201_3074_1
- 2012-004821-26 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bilateral Blepharospasm (BEB)
-
HugelCompletedEssential BlepharospasmKorea, Republic of
-
Medy-ToxCompletedEssential BlepharospasmKorea, Republic of
-
HugelCompletedEssential BlepharospasmKorea, Republic of
-
Medy-ToxCompleted
-
University of FloridaCompletedBenign Essential BlepharospasmUnited States
-
University Hospital, GrenobleCompletedBlepharospasm, Benign EssentialFrance
-
Silkiss Eye SurgeryJazz Pharmaceuticals; Smith-Kettlewell Eye Research Institute; Benign Essential...CompletedCBD | Blepharospasm | Blepharospasm, Benign EssentialUnited States
-
Oxford University Hospitals NHS TrustThe Dystonia Society of the United Kingdom; Globsource UK; Statsconsultancy Ltd...CompletedBlepharospasm
-
National Institute of Neurological Disorders and...Completed
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownBlepharospasm
Clinical Trials on IncobulinumtoxinA (Xeomin), 25 Units
-
Merz Pharmaceuticals GmbHCompletedCervical DystoniaUnited States
-
Merz Pharmaceuticals GmbHCompletedModerate to Severe Glabellar Frown LinesUnited States, Canada
-
Merz Pharmaceuticals GmbHCompletedModerate to Severe Glabellar Frown LinesUnited States
-
Merz Pharmaceuticals GmbHCompletedGlabellar LinesUnited States, Germany, Canada
-
Merz Pharmaceuticals GmbHCompletedLower Limb Spasticity Due to Cerebral PalsyPoland, Austria, Czechia, Estonia, France, Germany, Israel, Korea, Republic of, Romania, Russian Federation, Slovakia, Spain, Turkey, Ukraine
-
Merz Pharmaceuticals GmbHCompletedCerebral Palsy | SpasticityPoland, Russian Federation, Ukraine, United States, Argentina, Mexico
-
Merz Pharmaceuticals GmbHCompletedPost-stroke Spasticity of the Upper LimbPoland, United States, Czech Republic, Germany, Hungary, India, Russian Federation
-
Merz Pharmaceuticals GmbHCompletedGlabellar Frown LinesGermany
-
Merz Pharmaceuticals GmbHCompletedParkinson's Disease | Traumatic Brain Injury | Chronic Troublesome Sialorrhea | Post-strokeGermany, Poland
-
Merz Pharmaceuticals GmbHCompletedLower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral PalsyPoland, Austria, Czechia, Estonia, Germany, Israel, Korea, Republic of, Romania, Russian Federation, Slovakia, Turkey, Ukraine